Market Insights & Access Trends
Therapeutic Demand on the Rise: What’s Driving Procurement Across Emerging Markets
At Zenvor Global, we focus our therapeutic efforts where they matter most—across oncology, cardiovascular disease, diabetes, immunology, antiretrovirals, and anti-infectives. Each product we support is backed by market-specific insight and manufactured through trusted WHO, USFDA, EMA, MHRA-cGMP certified CMO/CDMO partners to ensure scalability, quality, and relevance. As governments continue to build healthcare systems that prioritize long-term access and affordability, we’re proud to support that progress.
The public health shift toward universal healthcare across countries in Latin America, Africa, and Asia is significantly increasing procurement in key therapeutic areas. From chronic disease to infectious outbreaks, national healthcare systems are actively investing in high-demand treatments that align with long-term public health strategies and institutional frameworks.
The Central America’s oncology drug market alone is projected to reach USD 344.4 million by 2025, highlighting the growing regional focus on cancer treatment infrastructure and accessibility. Cardiovascular care is also experiencing strong demand, particularly in Mexico, where the pharmaceutical market, including cardiovascular disease therapies, is expected to grow at a compound annual growth rate (CAGR) of 4.58%, reaching USD 9.15 billion by 2029.
Diabetes continues to be a major focus for government-led healthcare programs. In Mexico, the pharmaceutical market is forecasted to generate USD 7.65 billion in revenue by 2025, with diabetes medications playing a substantial role. Meanwhile, antiretroviral procurement remains a cornerstone of public health programs in Africa, particularly in Kenya, where national efforts are directed toward improving access to HIV/AIDS treatment through expanded public-private partnerships.
The demand for anti-infectives is also climbing steadily, driven by Kenya’s continued focus on combating diseases such as malaria and tuberculosis. While data on immunology procurement is less specific, treatments in this area remain integral to public healthcare strategies across all three regions, especially in response to evolving disease patterns and immune-related conditions.
Market potential across these regions reflects these procurement trends. Mexico stands out with a total addressable pharmaceutical market projected at USD 7.65 billion by 2025, with oncology accounting for USD 1.33 billion of that figure. This is expected to grow further to USD 9.15 billion by 2029. Costa Rica, a market highly reliant on imports, is forecasted to see pharmaceutical import growth from USD 751 million in 2019 to over USD 1.02 billion by 2024—representing a CAGR of 6.5%. In Kenya, while specific TAM figures are not widely published, strong demand for chronic and infectious disease treatments, paired with government-backed insurance programs, positions it as a key growth market for pharmaceutical investment.
